Hodgkin’s lymphoma: Post-autologous transplantation consolidation therapy
Acta Biomedica, ISSN: 2531-6745, Vol: 91, Issue: S-5, Page: 23-29
2020
- 2Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Article Description
A first-line chemotherapy program based on the ABVD regimen is currently considered the golden standard by most hematologists being able to achieve a cure without any need of subsequent therapies in >70% of patients with advanced-stage Hodgkin’s lymphoma (HL). To increase this percentage efforts in recent decades focused on the development of new therapeutic strategies. A first major effort was the introduction of the BEACOPP chemotherapy regimen which is able to increase the response rate and to reduce the need of salvage therapies. However this result did not demonstrate an advantage in terms of overall survival compared to ABVD mainly due to an excess of non lymphoma-related events in the follow-up phase. Here we describe three clinical cases of young HL patients who had relapsed/refractory disease after the induction chemotherapy. These three clinical cases provide practical and real world evidence in favor of the use of BV in monotherapy as consolidation treatment after autologous stem cells transplantation in patients with relapsed/ refractory HL.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85086356308&origin=inward; http://dx.doi.org/10.23750/abm.v91is-5.9914; http://www.ncbi.nlm.nih.gov/pubmed/32525131; https://dx.doi.org/10.23750/abm.v91is-5.9914; https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/9914
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know